Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11959141 Multigene analysis of tumor samples

Patent 11959141 was granted and assigned to Foundation Medicine on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Foundation Medicine

0

Current Assignee

Foundation Medicine

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Geoffrey Alan Otto0

Michelle Nahas0

Doron Lipson0

Date of Patent

April 16, 2024

0

Patent Application Number

155292370

Date Filed

December 4, 2015

0

Patent Citations

US Patent 9834822 Systems and methods to detect rare mutations and copy number variation

0

US Patent 9840743 Systems and methods to detect rare mutations and copy number variation

0

US Patent 9850523 Methods for multi-resolution analysis of cell-free nucleic acids

0

US Patent 9902992 Systems and methods to detect rare mutations and copy number variation

0

US Patent 9920366 Methods and systems for detecting genetic variants

0

US Patent 10041127 Systems and methods to detect rare mutations and copy number variation

0

US Patent 11118213 Optimization of multigene analysis of tumor samples

0

US Patent 11421265 Optimization of multigene analysis of tumor samples

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

Patent abstract

Methods of evaluating or providing a clonal profile of a subject interval, e.g., a subgenomic interval, or an expressed subgenomic interval (or of a cell containing the same), in a subject, are disclosed.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11959141 Multigene analysis of tumor samples

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.